Evidence map›Paper›PMID 42310073›Full record

ArticleNPJ precision oncology2026

LINC00312 increases gemcitabine sensitivity in nasopharyngeal carcinoma by recruiting PABPC1 and modulating PAX5-mediated transcription of LPLUNC1.

Zhen Guo, ZhiMin Zhang, Huai Liu, Feng Liu, Pan Chen, BinSheng He, Hui Wang, JiaoYang Lu

Abstract read
PubMed Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhen GuoHunan Provincial Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, the First Clinical College and the First Affiliated Hospital of Changsha Medical University, Changsha Medical University, Changsha, China.
ZhiMin ZhangDepartment of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
Huai LiuHunan Key Laboratory of Translational Radiation Oncology, Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Feng LiuHunan Key Laboratory of Translational Radiation Oncology, Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Pan ChenHunan Key Laboratory of Translational Radiation Oncology, Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
BinSheng HeHunan Provincial Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, the First Clinical College and the First Affiliated Hospital of Changsha Medical University, Changsha Medical University, Changsha, China.
Hui WangHunan Key Laboratory of Translational Radiation Oncology, Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. wanghui@hnca.org.cn.
JiaoYang LuHunan Provincial Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, the First Clinical College and the First Affiliated Hospital of Changsha Medical University, Changsha Medical University, Changsha, China. lulujiaoyang@163.com.

Funding

Changsha Outstanding Innovative Youth Training Plan No.kq2209024Hunan Provincial Science and Technology Department Program No.2023ZJ1120Outstanding Youth Project of Hunan Provincial Education Department No.24B0890The Science and Technology Innovation Program of Hunan Province No.2023RC3194
6 · The paper itself

Abstract

Gemcitabine resistance is an important factor in the treatment failure of nasopharyngeal carcinoma (NPC). LINC00312 has been reported to associate with chemotherapy toxicity and chemoradiotherapy response in NPC. However, the molecular mechanism by which LINC00312 regulates NPC sensitivity to gemcitabine is unclear. We found overexpression of LINC00312 or LPLUNC1 inhibited NPC cell proliferation, migration, invasion, and increased gemcitabine sensitivity. Mechanistically, LINC00312 bound to PABPC1 to increase PAX5 mRNA stability. PAX5 transcriptionally activated LPLUNC1 to inhibit the malignant phenotype of NPC and increase gemcitabine sensitivity. PAX5 depletion diminished the inhibitory effects of gemcitabine on cell viability, while LPLUNC1 overexpression restored chemosensitivity. Furthermore, PAX5 interacted with LINC00312 promoter to transcriptionally activate LINC00312. In turn, the LINC00312-PAX5 feedback axis upregulated LPLUNC1 to inhibit the progression of NPC and increase gemcitabine sensitivity in NPC. In conclusion, LINC00312 increased PAX5 mRNA stability by recruiting PABPC1, which promoted LPLUNC1 transcription to regulate sensitivity of NPC to gemcitabine. Meanwhile, PAX5 in turn transcriptionally activated LINC00312 to form a feedback axis, which further increased gemcitabine sensitivity.

Identifiers

PMID42310073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.